Physician profile
Janson Robb Becker
NPI 1073563136
$5,659.11
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,959 · 2020: $1,671 · 2021: $1,734 · 2022: $259 · 2023: $35.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.10 | 2019-2021 | |
| Novo Nordisk INC | $548.97 | 2019-2021 | |
| Pfizer INC. | $495.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $345.37 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $326.67 | 2019-2021 | |
| Abbott Laboratories | $302.43 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $294.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $287.66 | 2019-2021 | |
| Allergan, INC. | $278.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $239.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.25 | 2019-2021 | |
| Lilly USA, LLC | $231.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $225.08 | 2019-2021 | |
| Amgen INC. | $177.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $170.22 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $136.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.54 | 2019-2021 | |
| Daiichi Sankyo INC. | $55.38 | 2019-2020 | |
| Astellas Pharma US INC | $55.30 | 2019-2021 | |
| Dexcom, INC. | $43.83 | 2021 | |
| Edwards Lifesciences Corporation | $41.41 | 2020-2021 | |
| Insulet Corporation | $39.18 | 2021 | |
| Therapeuticsmd, INC. | $36.26 | 2019 | |
| Esperion Therapeutics, INC. | $35.35 | 2020 | |
| Gilead Sciences, INC. | $28.81 | 2020 | |
| Sanofi-Aventis U.S. LLC | $25.67 | 2019-2021 | |
| Acorda Therapeutics, INC | $23.39 | 2019 | |
| Aytu Biopharma, INC. | $23.10 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.14 | 2020 | |
| Si-Bone, INC. | $19.01 | 2020 | |
| Horizon Therapeutics Plc | $14.88 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.66 | 2020 | |
| Eisai INC. | $13.52 | 2021 | |
| Sanofi Pasteur INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janson Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.